Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.

Greppi M, Tabellini G, Patrizi O, Candiani S, Decensi A, Parolini S, Sivori S, Pesce S, Paleari L, Marcenaro E.

Int J Mol Sci. 2019 Feb 19;20(4). pii: E890. doi: 10.3390/ijms20040890. Review.

2.

A monoallelic activating mutation in RAC2 resulting in a combined immunodeficiency.

Lougaris V, Chou J, Beano A, Wallace JG, Baronio M, Gazzurelli L, Lorenzini T, Moratto D, Tabellini G, Parolini S, Seleman M, Stafstrom K, Xu H, Harris C, Geha RS, Plebani A.

J Allergy Clin Immunol. 2019 Apr;143(4):1649-1653.e3. doi: 10.1016/j.jaci.2019.01.001. Epub 2019 Jan 14. No abstract available.

PMID:
30654050
3.

CTLA-4 regulates human Natural Killer cell effector functions.

Lougaris V, Tabellini G, Baronio M, Patrizi O, Gazzurelli L, Mitsuiki N, Pozzi MR, Grimbacher B, Parolini S, Plebani A.

Clin Immunol. 2018 Sep;194:43-45. doi: 10.1016/j.clim.2018.06.010. Epub 2018 Jun 30. No abstract available.

PMID:
29966715
4.

Response to the Letter to the Editor Regarding "Functional evaluation of natural killer cell cytotoxic activity in NFKB-2 mutated patients".

Lougaris V, Tabellini G, Baronio M, Patrizi O, Parolini S, Plebani A.

Immunol Lett. 2018 Aug;200:16-17. doi: 10.1016/j.imlet.2018.05.004. Epub 2018 May 30. No abstract available.

PMID:
29859209
5.

Corrigendum: Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content.

Dobbs K, Tabellini G, Calzoni E, Patrizi O, Martinez P, Giliani SC, Moratto D, Al-Herz W, Cancrini C, Cowan M, Bleesing J, Booth C, Buchbinder D, Burns SO, Chatila TA, Chou J, Daza-Cajigal V, Ott de Bruin LM, de la Morena MT, Di Matteo G, Finocchi A, Geha R, Goyal RK, Hayward A, Holland S, Huang CH, Kanariou MG, King A, Kaplan B, Kleva A, Kuijpers TW, Lee BW, Lougaris V, Massaad M, Meyts I, Morsheimer M, Neven B, Pai SY, Parvaneh N, Plebani A, Prockop S, Reisli I, Soh JY, Somech R, Torgerson TR, Kim YJ, Walter JE, Gennery AR, Keles S, Manis JP, Marcenaro E, Moretta A, Parolini S, Notarangelo LD.

Front Immunol. 2017 Oct 10;8:1244. doi: 10.3389/fimmu.2017.01244. eCollection 2017.

6.

Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content.

Dobbs K, Tabellini G, Calzoni E, Patrizi O, Martinez P, Giliani SC, Moratto D, Al-Herz W, Cancrini C, Cowan M, Bleesing J, Booth C, Buchbinder D, Burns SO, Chatila TA, Chou J, Daza-Cajigal V, Ott de Bruin LM, de la Morena M, Di Matteo G, Finocchi A, Geha R, Goyal RK, Hayward A, Holland S, Huang CH, Kanariou MG, King A, Kaplan B, Kleva A, Kuijpers TW, Lee BW, Lougaris V, Massaad M, Meyts I, Morsheimer M, Neven B, Pai SY, Parvaneh N, Plebani A, Prockop S, Reisli I, Soh JY, Somech R, Torgerson TR, Kim YJ, Walter JE, Gennery AR, Keles S, Manis JP, Marcenaro E, Moretta A, Parolini S, Notarangelo LD.

Front Immunol. 2017 Jul 17;8:798. doi: 10.3389/fimmu.2017.00798. eCollection 2017. Erratum in: Front Immunol. 2017 Oct 10;8:1244.

7.

Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.

Tabellini G, Vairo D, Scomodon O, Tamassia N, Ferraro RM, Patrizi O, Gasperini S, Soresina A, Giardino G, Pignata C, Lougaris V, Plebani A, Dotta L, Cassatella MA, Parolini S, Badolato R.

J Allergy Clin Immunol. 2017 Aug;140(2):553-564.e4. doi: 10.1016/j.jaci.2016.10.051. Epub 2017 Jan 6.

PMID:
28069426
8.

NFKB1 regulates human NK cell maturation and effector functions.

Lougaris V, Patrizi O, Baronio M, Tabellini G, Tampella G, Damiati E, Frede N, van der Meer JWM, Fliegauf M, Grimbacher B, Parolini S, Plebani A.

Clin Immunol. 2017 Feb;175:99-108. doi: 10.1016/j.clim.2016.11.012. Epub 2016 Dec 3.

PMID:
27923702
9.

Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization.

Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, Moretta L, Moretta A, Marcenaro E.

J Allergy Clin Immunol. 2017 Jan;139(1):335-346.e3. doi: 10.1016/j.jaci.2016.04.025. Epub 2016 May 27.

PMID:
27372564
10.

p85α is an intrinsic regulator of human natural killer cell effector functions.

Lougaris V, Patrizi O, Baronio M, Tabellini G, Tampella G, Lanzi G, Salvini F, Trizzino A, Parolini S, Plebani A.

J Allergy Clin Immunol. 2016 Aug;138(2):605-608.e3. doi: 10.1016/j.jaci.2016.01.026. Epub 2016 Mar 23. No abstract available.

PMID:
27016802
11.

B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape.

Pesce S, Tabellini G, Cantoni C, Patrizi O, Coltrini D, Rampinelli F, Matta J, Vivier E, Moretta A, Parolini S, Marcenaro E.

Oncoimmunology. 2015 Jan 22;4(4):e1001224. eCollection 2015 Apr.

12.

Inherited DOCK2 Deficiency in Patients with Early-Onset Invasive Infections.

Dobbs K, Domínguez Conde C, Zhang SY, Parolini S, Audry M, Chou J, Haapaniemi E, Keles S, Bilic I, Okada S, Massaad MJ, Rounioja S, Alwahadneh AM, Serwas NK, Capuder K, Çiftçi E, Felgentreff K, Ohsumi TK, Pedergnana V, Boisson B, Haskoloğlu Ş, Ensari A, Schuster M, Moretta A, Itan Y, Patrizi O, Rozenberg F, Lebon P, Saarela J, Knip M, Petrovski S, Goldstein DB, Parrott RE, Savas B, Schambach A, Tabellini G, Bock C, Chatila TA, Comeau AM, Geha RS, Abel L, Buckley RH, İkincioğulları A, Al-Herz W, Helminen M, Doğu F, Casanova JL, Boztuğ K, Notarangelo LD.

N Engl J Med. 2015 Jun 18;372(25):2409-22. doi: 10.1056/NEJMoa1413462.

13.

The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.

Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2015 Jul 10;6(19):17147-60.

14.

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.

Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2015 Mar 30;6(9):6597-610.

15.

Defective natural killer-cell cytotoxic activity in NFKB2-mutated CVID-like disease.

Lougaris V, Tabellini G, Vitali M, Baronio M, Patrizi O, Tampella G, Biasini A, Moratto D, Parolini S, Plebani A.

J Allergy Clin Immunol. 2015 Jun;135(6):1641-3. doi: 10.1016/j.jaci.2014.11.038. Epub 2015 Jan 17. No abstract available.

PMID:
25605273
16.

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.

Simioni C, Cani A, Martelli AM, Zauli G, Tabellini G, McCubrey J, Capitani S, Neri LM.

Oncotarget. 2014 Oct 30;5(20):10034-47.

17.

Primitive neuroectodermal tumor in an ovarian cystic teratoma: natural killer and neuroblastoma cell analysis.

Tabellini G, Benassi M, Marcenaro E, Coltrini D, Patrizi O, Ricotta D, Rampinelli F, Moretta A, Parolini S.

Case Rep Oncol. 2014 Jan 24;7(1):70-8. doi: 10.1159/000357802. eCollection 2014 Jan.

18.

Occurrence of nodular lymphocyte-predominant hodgkin lymphoma in hermansky-pudlak type 2 syndrome is associated to natural killer and natural killer T cell defects.

Lorenzi L, Tabellini G, Vermi W, Moratto D, Porta F, Notarangelo LD, Patrizi O, Sozzani S, de Saint Basile G, Latour S, Pace D, Lonardi S, Facchetti F, Badolato R, Parolini S.

PLoS One. 2013 Nov 26;8(11):e80131. doi: 10.1371/journal.pone.0080131. eCollection 2013.

19.

Effects of opioid therapy on human natural killer cells.

Tabellini G, Borsani E, Benassi M, Patrizi O, Ricotta D, Caimi L, Lanzi R, Micheli F, Iorno V, Bettaglio R, Rezzani R, Rodella LF, Parolini S.

Int Immunopharmacol. 2014 Jan;18(1):169-74. doi: 10.1016/j.intimp.2013.11.015. Epub 2013 Nov 25.

PMID:
24287448
20.

Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.

Buontempo F, Orsini E, Martins LR, Antunes I, Lonetti A, Chiarini F, Tabellini G, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Cappellini A, Barata JT, Martelli AM.

Leukemia. 2014 Mar;28(3):543-53. doi: 10.1038/leu.2013.349. Epub 2013 Nov 20.

PMID:
24253024
21.

Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism.

Dotta L, Parolini S, Prandini A, Tabellini G, Antolini M, Kingsmore SF, Badolato R.

Orphanet J Rare Dis. 2013 Oct 17;8:168. doi: 10.1186/1750-1172-8-168. Review.

22.

Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.

Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, Tabellini G, Ricci F, Tazzari PL, Pagliaro P, McCubrey JA, Capitani S.

Leukemia. 2014 Apr;28(4):739-48. doi: 10.1038/leu.2013.226. Epub 2013 Jul 29.

PMID:
23892718
23.

The emerging multiple roles of nuclear Akt.

Martelli AM, Tabellini G, Bressanin D, Ognibene A, Goto K, Cocco L, Evangelisti C.

Biochim Biophys Acta. 2012 Dec;1823(12):2168-78. doi: 10.1016/j.bbamcr.2012.08.017. Epub 2012 Aug 31. Review.

24.

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.

Bressanin D, Evangelisti C, Ricci F, Tabellini G, Chiarini F, Tazzari PL, Melchionda F, Buontempo F, Pagliaro P, Pession A, McCubrey JA, Martelli AM.

Oncotarget. 2012 Aug;3(8):811-23.

25.

Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a.

Buontempo F, Chiarini F, Bressanin D, Tabellini G, Melchionda F, Pession A, Fini M, Neri LM, McCubrey JA, Martelli AM.

Cell Cycle. 2012 Jul 1;11(13):2467-75. doi: 10.4161/cc.20859. Epub 2012 Jul 1.

PMID:
22713244
26.

Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.

Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Capitani S, Martelli AM.

Leukemia. 2012 Nov;26(11):2336-42. doi: 10.1038/leu.2012.136. Epub 2012 May 22.

PMID:
22614243
27.

Exome sequencing reveals a pallidin mutation in a Hermansky-Pudlak-like primary immunodeficiency syndrome.

Badolato R, Prandini A, Caracciolo S, Colombo F, Tabellini G, Giacomelli M, Cantarini ME, Pession A, Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Saunders CJ, Zhang L, Schroth GP, Plebani A, Parolini S, Kingsmore SF.

Blood. 2012 Mar 29;119(13):3185-7. doi: 10.1182/blood-2012-01-404350. No abstract available.

28.

A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP.

Lanzi G, Moratto D, Vairo D, Masneri S, Delmonte O, Paganini T, Parolini S, Tabellini G, Mazza C, Savoldi G, Montin D, Martino S, Tovo P, Pessach IM, Massaad MJ, Ramesh N, Porta F, Plebani A, Notarangelo LD, Geha RS, Giliani S.

J Exp Med. 2012 Jan 16;209(1):29-34. doi: 10.1084/jem.20110896. Epub 2012 Jan 9.

29.

PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy.

Martelli AM, Tabellini G, Ricci F, Evangelisti C, Chiarini F, Bortul R, McCubrey JA, Manzoli FA.

Adv Biol Regul. 2012 Jan;52(1):214-27. No abstract available.

PMID:
21983557
30.

AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications.

Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M, Falcieri E, Bortul R, Melchionda F, Iacobucci I, Pagliaro P, Martinelli G, Pession A, Barata JT, McCubrey JA, Martelli AM.

Leukemia. 2012 Jan;26(1):91-100. doi: 10.1038/leu.2011.269. Epub 2011 Oct 4.

PMID:
21968881
31.

Severe impairment of IFN-γ and IFN-α responses in cells of a patient with a novel STAT1 splicing mutation.

Vairo D, Tassone L, Tabellini G, Tamassia N, Gasperini S, Bazzoni F, Plebani A, Porta F, Notarangelo LD, Parolini S, Giliani S, Badolato R.

Blood. 2011 Aug 18;118(7):1806-17. doi: 10.1182/blood-2011-01-330571. Epub 2011 Jul 19.

32.

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.

Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E, Chiarini F, Bortul R, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Martelli AM.

Leukemia. 2011 May;25(5):781-91. doi: 10.1038/leu.2011.20. Epub 2011 Feb 18.

PMID:
21331075
33.

GPR56 as a novel marker identifying the CD56dull CD16+ NK cell subset both in blood stream and in inflamed peripheral tissues.

Della Chiesa M, Falco M, Parolini S, Bellora F, Petretto A, Romeo E, Balsamo M, Gambarotti M, Scordamaglia F, Tabellini G, Facchetti F, Vermi W, Bottino C, Moretta A, Vitale M.

Int Immunol. 2010 Feb;22(2):91-100. doi: 10.1093/intimm/dxp116. Epub 2009 Dec 14.

PMID:
20008459
34.

Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.

Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, Evangelisti C, Martinelli G, Bontadini A, Cocco L, McCubrey JA, Martelli AM.

Cancer Res. 2008 Nov 15;68(22):9394-403. doi: 10.1158/0008-5472.CAN-08-2815.

35.

The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion.

Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, Martinelli G, McCubrey JA, Martelli AM.

Leukemia. 2007 May;21(5):886-96. Epub 2007 Mar 15.

PMID:
17361225
36.

Nuclear diacylglycerol kinases: emerging downstream regulators in cell signaling networks.

Evangelisti C, Bortul R, Falà F, Tabellini G, Goto K, Martelli AM.

Histol Histopathol. 2007 May;22(5):573-9. doi: 10.14670/HH-22.573. Review.

PMID:
17330812
37.

The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues.

Parolini S, Santoro A, Marcenaro E, Luini W, Massardi L, Facchetti F, Communi D, Parmentier M, Majorana A, Sironi M, Tabellini G, Moretta A, Sozzani S.

Blood. 2007 May 1;109(9):3625-32. Epub 2007 Jan 3.

38.

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

Martelli AM, Nyåkern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L.

Leukemia. 2006 Jun;20(6):911-28. Review.

PMID:
16642045
39.

Nuclear expression of diacylglycerol kinases: possible involvement in DNA replication.

Evangelisti C, Bortul R, Tabellini G, Papa V, Cocco L, Martelli AM.

Eur J Histochem. 2006 Jan-Mar;50(1):9-13. Review.

PMID:
16584979
40.

Nuclear phosphoinositide specific phospholipase C (PI-PLC)-beta 1: a central intermediary in nuclear lipid-dependent signal transduction.

Martelli AM, Fiume R, Faenza I, Tabellini G, Evangelista C, Bortul R, Follo MY, Falà F, Cocco L.

Histol Histopathol. 2005 Oct;20(4):1251-60. doi: 10.14670/HH-20.1251. Review.

PMID:
16136505
41.

Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias.

Tabellini G, Tazzari PL, Bortul R, Evangelisti C, Billi AM, Grafone T, Martinelli G, Baccarani M, Martelli AM.

Br J Haematol. 2005 Sep;130(5):716-25.

PMID:
16115127
42.

Rabphilin localizes with the cell actin cytoskeleton and stimulates association of granules with F-actin cross-linked by {alpha}-actinin.

Baldini G, Martelli AM, Tabellini G, Horn C, Machaca K, Narducci P, Baldini G.

J Biol Chem. 2005 Oct 14;280(41):34974-84. Epub 2005 Jul 25.

43.

Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.

Bortul R, Tazzari PL, Billi AM, Tabellini G, Mantovani I, Cappellini A, Grafone T, Martinelli G, Conte R, Martelli AM.

Br J Haematol. 2005 Jun;129(5):677-86.

PMID:
15916691
44.

Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias.

Martelli AM, Tabellini G, Bortul R, Tazzari PL, Cappellini A, Billi AM, Cocco L.

Histol Histopathol. 2005 Jan;20(1):239-52. doi: 10.14670/HH-20.239. Review.

PMID:
15578442
45.

Nuclear diacylglycerol kinase-theta is activated in response to nerve growth factor stimulation of PC12 cells.

Tabellini G, Billi AM, Falà F, Cappellini A, Evagelisti C, Manzoli L, Cocco L, Martelli AM.

Cell Signal. 2004 Nov;16(11):1263-71.

PMID:
15337525
46.

Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells.

Tabellini G, Cappellini A, Tazzari PL, Falà F, Billi AM, Manzoli L, Cocco L, Martelli AM.

J Cell Physiol. 2005 Feb;202(2):623-34.

PMID:
15316930
47.

Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway.

Tabellini G, Tazzari PL, Bortul R, Billi AM, Conte R, Manzoli L, Cocco L, Martelli AM.

Br J Haematol. 2004 Aug;126(4):574-82.

PMID:
15287952
48.

Intranucleolar localization of DNA topoisomerase IIalpha is a distinctive feature of necrotic, but not of apoptotic, Jurkat T-cells.

Falcieri E, Burattini S, Bortul R, Luchetti F, Tabellini G, Tazzari PL, Cappellini A, Cocco L, Martelli AM.

Microsc Res Tech. 2003 Oct 15;62(3):192-200.

PMID:
14506684
49.

A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.

Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, Ruggeri A, Conte R, Cocco L.

Leukemia. 2003 Sep;17(9):1794-805.

PMID:
12970779
50.

Supplemental Content

Loading ...
Support Center